← Adicet Bio, Inc. (ACET) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Adicet Bio, Inc. (ACET)
Pharmaceutical Preparations · market cap $80M · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Adicet Bio (ACET) is a small-cap biopharma with 152 employees and an ~$80M market cap developing ADI-270, a Phase 2 asset targeting Clear Cell Renal Cell Carcinoma. The company recently completed a Phase 2 trial (June 15, 2026) and carries only ~$36.2M in cash against a runway of roughly 5 months, creating acute financing pressure ahead of data readout.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ADI-270 | Phase 2 | Clear Cell Renal Cell Carcinoma |
Price & technical context
3-month
-27.5%
6-month
-5.9%
12-month
-50.0%
52-wk range
$6.11–$16.64
vs 50-day MA
-24.1%
vs 200-day MA
-17.9%
Realized vol
81.7%
Max drawdown
-75.0%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ACET (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.